{'52WeekChange': 0.0069123507,
 'SandP52WeekChange': None,
 'address1': '863 Mitten Road',
 'address2': 'Suite 102',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.29,
 'askSize': 2200,
 'averageDailyVolume10Day': 781187,
 'averageVolume': 2045492,
 'averageVolume10days': 781187,
 'beta': 2.038483,
 'beta3Year': None,
 'bid': 4.4,
 'bidSize': 1300,
 'bookValue': 2.148,
 'category': None,
 'circulatingSupply': None,
 'city': 'Burlingame',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.43,
 'dayLow': 4.1,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.104,
 'enterpriseToRevenue': None,
 'enterpriseValue': 54189368,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.563857,
 'fiftyTwoWeekHigh': 6.88,
 'fiftyTwoWeekLow': 1.01,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 13846634,
 'forwardEps': -1.49,
 'forwardPE': -2.8791945,
 'fromCurrency': None,
 'fullTimeEmployees': 52,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.06313,
 'heldPercentInstitutions': 0.75637,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/corvuspharma.com',
 'longBusinessSummary': 'Corvus Pharmaceuticals, Inc., a clinical stage '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization of immuno-oncology therapies. '
                        'Its lead product candidate is CPI-444, an oral, small '
                        'molecule antagonist of the A2A receptor that is in '
                        'Phase I/Ib clinical trial for adenosine, an immune '
                        'checkpoint. The company is also developing CPI-006, '
                        'an anti-CD73 monoclonal antibody that inhibits the '
                        'production of adenosine; an antagonist of the '
                        'adenosine A2B receptor; and CPI-818, a small molecule '
                        'covalent inhibitor of interleukin-2 inducible kinase. '
                        'Corvus Pharmaceuticals, Inc. was founded in 2014 and '
                        'is based in Burlingame, California.',
 'longName': 'Corvus Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 119919224,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_279359732',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -47964000,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.25,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650-900-4520',
 'previousClose': 4.37,
 'priceHint': 4,
 'priceToBook': 1.9972067,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.43,
 'regularMarketDayLow': 4.1,
 'regularMarketOpen': 4.25,
 'regularMarketPreviousClose': 4.37,
 'regularMarketPrice': 4.25,
 'regularMarketVolume': 272490,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 27953200,
 'sharesPercentSharesOut': 0.0152,
 'sharesShort': 424168,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 327762,
 'shortName': 'Corvus Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.031600002,
 'shortRatio': 3.61,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'CRVS',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.633,
 'twoHundredDayAverage': 3.5521944,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '956d43b5-68cb-3c6d-b466-9b34fd9537d2',
 'volume': 272490,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.corvuspharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94010'}